Company profile
Microbiosensor Limited
Home - microbiosensor - microbiosensor
Welcome to MicroBioSensor
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts filed
AccountsLast accounts made up date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQzNzk4MTgyOGFkaXF6a2N4 | Paper/PDF filed
Published 08 Oct 2024 06:16
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
Microbiosensor is a medical device company developing disposable point-of-care safety monitors for detecting microbial infection. Microbiological monitoring is especially important for long-term users of medical devices. Medical device use is one of the highest risk factors for nosocomial infection, affecting nearly 2 million patients and killing approximately 90,000 annually in the US alone. At risk groups include patients with chronic wounds, such as diabetic leg ulcers, or those requiring long-term invasive medical device intervention, such as kidney dialysis patients. Microbiosensor Ltd is addressing this need for improved infection monitoring head-on, by offering the market unique, robust and inexpensive diagnostic solutions. Our devices provide continuous safety monitoring, enhancing patient care by allowing earlier intervention than is currently possible. This will improve treatment outcomes and ultimately help in the fight against multi-drug resistance, by improving the management of the remaining arsenal of effective antibiotic drugs.
MicroBioSensor develops medical devices that create signals when an infection begins to escalate, aiming to facilitate prompt intervention.
Project impact
Microbiosensor has secured around £4m funding to develop its technology. The company's first product is expected to be CE marked in 2018, and should save each EU healthcare provider around £10m pa.
Public funding
Projects
From niche 'in clinic' diagnostic to high-volume home-use medical product
9 Jul 2020 to 9 Jul 2023
From niche 'in clinic' diagnostic to high-volume home-use medical product
PeriFAST: a new product to rapidly identify effective antibiotics to treat peritonitis in vulnerable kidney and liver failure patients.
1 Jun 2020 to 31 May 2022
Patients with advanced kidney disease, who are reliant on peritoneal dialysis (PD), and advanced liver disease patients, with liver cirrhosis, are both at risk of life-threatening infection in the abdomen, referred to as 'peritonitis'. This develops quickly, and typically requires hospital admission. The choice of antibiotic therapy has to be made by doct...
Same-day Test for Antibiotic Resistance (STAR)
1 May 2019 to 31 Jan 2022
"The misdiagnosis and incorrect treatment of Urinary Tract Infections (UTIs) is a significant global healthcare problem and a contributory factor to growing antibiotic resistance levels. UTIs are the most common non-intestinal infection in women worldwide (over 15-million new infections p.a.). In the UK they are the 3rd most common reason for emergency ad...
Evaluation, Prototyping and Production Pathway of a Diagnostic for Peritoneal Dialysis Infection
1 Feb 2017 to 31 Jan 2019
Increasing numbers of people are suffering from kidney failure, particularly resulting from diabetes. Patients with kidney failure can have two types of dialysis; Peritoneal- or Haemo-dialysis. Peritoneal dialysis can be done at home and gives the patient the most freedom and flexibility, it is also cheaper than haemodialysis. However, it carries a risk o...